Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Update

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the target of a significant decrease in short interest in the month of January. As of January 15th, there was short interest totalling 31,500 shares, a decrease of 58.7% from the December 31st total of 76,200 shares. Based on an average trading volume of 787,700 shares, the days-to-cover ratio is currently 0.0 days.

Astellas Pharma Stock Up 0.7 %

Astellas Pharma stock opened at $9.84 on Wednesday. Astellas Pharma has a twelve month low of $9.05 and a twelve month high of $13.14. The stock’s fifty day simple moving average is $9.89 and its 200-day simple moving average is $10.99. The company has a current ratio of 1.10, a quick ratio of 0.86 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $17.81 billion, a P/E ratio of 46.87 and a beta of 0.34.

Astellas Pharma (OTCMKTS:ALPMY) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $0.13 earnings per share for the quarter. The business had revenue of $3.11 billion for the quarter. Astellas Pharma had a return on equity of 10.40% and a net margin of 3.26%. As a group, equities analysts expect that Astellas Pharma will post 0.61 earnings per share for the current fiscal year.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.